BMY vs ILMN: fair value comparison
Bristol-Myers Squibb Company and Illumina, Inc. · Updated 2026-09-07
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, ILMN currently sits closer to the top of our discount ranking.
| BMY | ILMN | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $66.82 | $198.16 |
| 12-month range | $46.02–$66.92 | $102.26–$198.16 |
| Sector rank | #100 of 113 Healthcare | #98 of 113 Healthcare |
| Quality grade | C | C |
| Leverage | High | Moderate |
| Margin trend | Expanding | Expanding |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Mixed |
| DCF cross-check | Undervalued | — |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: BMY fair value analysis · ILMN fair value analysis